Hereditary Angioedema Therapeutic Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions and By Key Players: BioCryst Pharmaceuticals, Inc. (BCRX), Ionis Pharmaceuticals, Inc. (IONS)

Acknowledging the kind of traction gained by this market, industrydataanalytics recently published a study report asserts the global Hereditary Angioedema Therapeutic Market size is projected to accrue voluminously by 2027 registering a phenomenal CAGR of 8.7% during the review period (2022 to 2027).

Hereditary Angioedema Therapeutic Market Overview:

Hereditary Angioedema Therapeutic is the treatment for Hereditary Angioedema. Growing cases of hereditary angioedema (HAE) globally is a key market driver.

The hereditary angioedema therapeutic market is being driven by the increasing awareness-raising activities among the general population. The lack of awareness of hereditary angioedema therapeutic is the main reason for misdiagnosis, which in turn results in patients receiving insufficient care. Some patients with hereditary angioedema are misdiagnosed with appendicitis, gastrointestinal disorders, and other non-allergic angioedema conditions. A small number of patients misdiagnosed for the disorder provides a large pool of patients with significant medical needs. This is expected to be a key market driver for hereditary angioedema therapeutic in the coming years.

Recent Development:

BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

RESEARCH TRIANGLE PARK, N.C., June 06, 2022 -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Health Canada has approved oral, once-daily ORLADEYO® (berotralstat) for the routine prevention of recurrent hereditary angioedema (HAE) attacks in patients 12 years and older.

“Today is a momentous day for the Canadian HAE community,” said Jacquie Badiou, president of HAE Canada. “HAE carries with it a severe burden on patients and their families, much of which stems from the unpredictable attacks they experience even when actively managing their disease. We have seen important treatment advancements in recent years, and I believe the first oral preventive therapy for HAE will be a welcome option for many Canadians who are living with this rare condition.”

What are the major Applications, Types, and Regions of the Hereditary Angioedema Therapeutics Market?

By Type, it is segmented into

• Intravenous


• Subcutaneous


• Oral


• Others

By Applications, it is segmented into

• Hospitals


• Clinics


• Others

Hereditary Angioedema Therapeutic Market Regional Analysis

North America accounted for a leading share in the market in terms of revenue in 2018 owing to new product launches by major players, better reimbursement scenario, and well-developed healthcare infrastructure. For instance, in February 2018, the FDA granted regulatory approval for Cinryze for expanded application in pediatric patients aged 6 years and above. Asia Pacific is expected to witness the fastest growth during the forecast period. Growing patient awareness levels, coupled with the launch of novel therapies for hereditary angioedema management, is expected to drive the market in the region.

•  North America
  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East & Africa
  
  
  • Latin America
  
  
  
  

The Hereditary Angioedema Therapeutic market has been studied across North America, Europe, Asia Pacific, Latin America, the Middle East & Africa. The Asia Pacific is expected to dominate the most significant market owing to rising demand for natural gas mainly across the countries like India, China, and Japan among others. China has the fastest-growing investment in LNG stations, as its focus on cleaner energy for industrial and commercial transportation is anticipated to drive the market across the region. Following Asia-Pacific, Europe, and North America and have implemented stringent laws to reduce emissions & are more focused on renewable energy projects and energy-efficient sectors the rise in commercial and industrial transportation has led to the expansion of LNG stations across the region, and are the second-largest region in the global Hereditary Angioedema Therapeutic market. In Latin America government has reduced the importation tariffs for LNG-powered vehicles, enhancing the market landscape of Hereditary Angioedema Therapeutic positively.

Hereditary Angioedema Therapeutic Market Report Scope:

Key Takeaways from this Hereditary Angioedema Therapeutic Report

• Evaluate Hereditary Angioedema Therapeutic market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level - for product types, end use applications and by different industry verticals.


• Understand the different dynamics influencing the market - growth driving factors, specific challenges and hidden opportunities.


• Get in-depth insights on your competitor performance – revenue, shares, business strategies, financial benchmarking, product benchmarking, SWOT analysis and more.


• Analyze the sales and distribution channels across geographies to enhance top-line revenues.

All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.

Frequently Asked Questions

What is the study period of this market?

The Hereditary Angioedema Therapeutic Market is studied from 2017 - 2027.

Who are the key players in Hereditary Angioedema Therapeutic Market?

BioCryst Pharmaceuticals, Inc. (BCRX), Ionis Pharmaceuticals, Inc. (IONS), Pharming Group, CSL Limited, Shire, Attune Pharma, Adverum Biotechnologies, KalVista Pharma. Others.

What are the significant types of Hereditary Angioedema Therapeutic Market?

Intravenous, Subcutaneous, Oral, Others.

What are the major end-use applications of Hereditary Angioedema Therapeutic Market?

Hospitals, Clinics, Others.

What segments are covered in the Hereditary Angioedema Therapeutic Market report?

The Global Hereditary Angioedema Therapeutic Market is segmented on the basis of Product, Application, and Geography.

How can I get a sample report/company profile for the Hereditary Angioedema Therapeutic Market?

The sample report for the Hereditary Angioedema Therapeutic Market can be obtained on demand from the website. Also, the 24*7 chat support & direct call services are provided to procure the sample report.